Chronic lymphocytic leukaemia+1
RecruitingStudy on Venetoclax and Epcoritamab for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Study on Venetoclax and Epcoritamab for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- Disease:Chronic lymphocytic leukaemiaB-cell small lymphocytic lymphoma
- Substances:EpcoritamabVenetoclax
Germany- Participants:18–64 years · 65+ years
- Substances:Epcoritamab
- Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting










